Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study on the Safety and Efficacy of BM32 in Grass Pollen Allergy
2012-000442-35Phase 2Completed
- Sponsor
- Biomay AG
- Start
- Feb 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BM32 in grass pollen allergy and seasonal allergic rhinitis (SAR) (3 arms), sponsored by Biomay AG. Started Feb 2012; status: completed.
02
Drugs
BM32
03
Conditions
grass pollen allergyseasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2012-000442-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000442-35.